These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9027603)

  • 1. Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
    Kensler TW; Groopman JD
    J Cell Biochem Suppl; 1996; 25():85-91. PubMed ID: 9027603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological relevance of adduct detection to the chemoprevention of cancer.
    Sharma RA; Farmer PB
    Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts.
    Yu MW; Lien JP; Liaw YF; Chen CJ
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):613-9. PubMed ID: 8824363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinogen biomarkers for lung or oral cancer chemoprevention trials.
    Hecht SS
    IARC Sci Publ; 2001; 154():245-55. PubMed ID: 11220664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biomarkers for aflatoxins and their application to human cancer prevention.
    Groopman JD; Wogan GN; Roebuck BD; Kensler TW
    Cancer Res; 1994 Apr; 54(7 Suppl):1907s-1911s. PubMed ID: 8137310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
    De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
    J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer.
    Groopman JD; Wang JS; Scholl P
    Can J Physiol Pharmacol; 1996 Feb; 74(2):203-9. PubMed ID: 8723033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure biomarkers in chemoprevention studies of liver cancer.
    Wild CP; Turner PC
    IARC Sci Publ; 2001; 154():215-22. PubMed ID: 11220661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinogen-DNA and carcinogen-protein adducts in molecular epidemiology.
    Wild CP; Pisani P
    IARC Sci Publ; 1997; (142):143-58. PubMed ID: 9354917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials.
    Kensler TW; Groopman JD; Wogan GN
    IARC Sci Publ; 1996; (139):237-48. PubMed ID: 8923034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and validation of biomarkers for chemoprevention: the contribution of epidemiology.
    Vineis P; Veglia F
    IARC Sci Publ; 2001; 154():57-68. PubMed ID: 11220669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer.
    Kensler TW; Gange SJ; Egner PA; Dolan PM; Muñoz A; Groopman JD; Rogers AE; Roebuck BD
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):603-10. PubMed ID: 9264273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The uses of carcinogen-DNA adduct measurement in establishing mechanisms of mutagenesis and in chemoprevention.
    Baird WM; Mahadevan B
    Mutat Res; 2004 Mar; 547(1-2):1-4. PubMed ID: 15013693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of chemicals on liver cancer risk.
    Wogan GN
    Semin Cancer Biol; 2000 Jun; 10(3):201-10. PubMed ID: 10936069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of DNA adducts to identify human health risk from exposure to hazardous environmental pollutants: the increasing role of mass spectrometry in assessing biologically effective doses of genotoxic carcinogens.
    Farmer PB; Singh R
    Mutat Res; 2008; 659(1-2):68-76. PubMed ID: 18468947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogen-DNA adducts as a biomarker for cancer risk.
    Rundle A
    Mutat Res; 2006 Aug; 600(1-2):23-36. PubMed ID: 16824556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Individual predisposition to lung neoplasm--the role of genes involved in metabolism of carcinogens].
    Butkiewicz D; Chorazy M
    Postepy Hig Med Dosw; 1999; 53(5):655-73. PubMed ID: 10645142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts.
    Gyorffy E; Anna L; Kovács K; Rudnai P; Schoket B
    Mutagenesis; 2008 Jan; 23(1):1-18. PubMed ID: 17989146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.